"如果选择自费进行CAR—T细胞疗法，将付出掏空家庭所有积蓄的代价。"面对昂贵的治疗费用，不久 前被诊断癌症的刘先生相当惆怅。 刘先生直言，若自己选择CAR—T细胞疗法，单次治疗费用超过百万元，自己实在不愿因此令整个家庭 变得拮据。 如何不让昂贵的创新药治疗费用"阻碍"病人就诊，正成为社会日益关注的一大热门话题。 北京中健联健康服务促进中心副会长濮亮向记者表示，创新药的广泛应用亟需可持续、高效率的支付体 系支撑。 为了推动创新药发展与解决创新药可及性问题，近年国家出台一系列政策，包括支持创新药进入基本医 保目录与商业健康保险创新药品目录（下称"商保创新药目录"），持续提高创新药多元支付能力，力图 打通创新药的"最后一公里"。 随着中国老龄化社会来临与民众治疗需求日益加大，中国已跃居全球第二大药品支出市场，年均复合增 长率超过3%。其中，创新药成为市场增长的主要驱动力。 数据显示，去年中国创新药市场规模达到约1620亿元，同比增长16%。与此对应的是，全球创新药在中 国首发的趋势持续增强，2017年仅有9%新药在中国首发上市，2023年这个数值上升至29%。 但是，光靠基本医保难以全面覆盖所有创新药物的医疗支出 ...

Core Insights - Roche (RHHBY.US) announced statistically significant results from the final overall survival (OS) outcomes of the Phase III APHINITY study for patients with HER2-positive early breast cancer, showing a 17% reduction in death risk for those treated with Perjeta, Herceptin, and chemotherapy compared to those receiving Herceptin, chemotherapy, and placebo [1][2] Group 1 - The APHINITY study was a global, Phase III, randomized, double-blind, placebo-controlled trial involving 4,804 operable HER2-positive early breast cancer patients [1] - The primary endpoint of the study was invasive disease-free survival, with secondary endpoints including cardiac and overall safety, overall survival, and health-related quality of life [1] Group 2 - Ten-year survival rates showed that patients receiving the Perjeta regimen had a survival rate of 91.6%, compared to 89.8% for those receiving Herceptin, chemotherapy, and placebo (HR=0.83, 95% CI: 0.69-1.00, p=0.044) [2] - In the pre-specified subgroup of lymph node-positive patients, the death risk was reduced by 21% (HR=0.79, 95% CI: 0.64-0.97) [2] - The previously reported benefits in invasive disease-free survival were maintained (HR=0.79, 95% CI: 0.68-0.92), with no observed benefits in the lymph node-negative subgroup [2] - Safety profiles, including cardiac safety, were consistent with previous studies, with no new or unexpected safety signals identified [2]